These shorts are recalcitrant. They are stuck on the multiple drug failures of this company: Sulonex failed in 2008 for peripheral neuropathy in diabetics; Perifosine for colon cancer failed in 2012, and then when Zerenex worked, they are still convinced that the drug will lose out to generics. I can sympathize with the shorts argument that this company can't get a drug through the FDA if its life depended on it, but alas, it can and will. Passionate shorts are just like passionate longs: they don't let go until it's too late. It's about to be too late for the shorts, once a short squeeze happens when phase 2 data on NDD-CKD get released. KERX is about to explode upward.